South San Francisco, United States
Alumis, founded in 2021 and headquartered in the United States, is making strides in the biotechnology, health care, and life sciences industries. The company is committed to transforming the lives of patients with immune-mediated diseases through a precise, targeted approach. By focusing on optimizing patient outcomes, Alumis aims to replace broad immunosuppression with therapies tailored precisely to individual patient needs.
Utilizing advanced data analytics, Alumis seeks to innovate patient care by carefully selecting the right targets, molecules, indications, and endpoints. Its mission is further supported by a team of seasoned professionals committed to pioneering transformative therapies.
With a robust financial backing evident in their recent $259.00M Series C investment on 06 March 2024, Alumis is anchored by significant investors like HBM Healthcare Investments, Lilly Asia Ventures, and Foresite Capital, among others. This financial support underscores investor confidence in Alumis' pioneering approach and capacity for innovation in addressing immune dysfunction.
ENDPOINT HEALTH
Expansion Therapeutics